Combined therapy with pioglitazone and FGF21 mRNA synergistically ameliorates metabolic disorders in NAFLD rats

Combined therapy with pioglitazone and FGF21 mRNA synergistically ameliorates metabolic disorders in NAFLD rats

Background: Current study aims to investigate the ameliorative effect of pioglitazone (PIO) combined with mRNA encoding FGF21 (termed mFGF21) on the metabolic disorders in rats with nonalcoholic fatty liver disease (NAFLD) and its potential mechanism. Methods: In vitro functional activity of FGF21 p...

Full description

Bibliographic Details
Main Authors: Xixia Huang, Zuyu Xia, Yiqin Huang, Yifei Sun, Lina Zhang, Wenjian Xiong, Ziyan Zhang
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:Heliyon
Subjects:
Fibroblast growth factor 21
Pioglitazone
mRNA
Non-alcoholic fatty liver disease
SHP1/AMPK pathway
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844023023538

Internet

http://www.sciencedirect.com/science/article/pii/S2405844023023538

Similar Items